Science News
from research organizations

New pill regimens cure hardest-to-treat hepatitis C patients

Date:
July 28, 2014
Source:
University of Texas Health Science Center at San Antonio
Summary:
Scientists have now identified a simple, pill-only treatment for hepatitis C that can cure 93 percent of patients in 12 weeks. This replaces a long and complicated treatment with many serious side effects.
Share:
       
FULL STORY

Scientists have now identified a simple, pill-only treatment for hepatitis C that can cure 93 percent of patients in 12 weeks.
Credit: © DOC RABE Media / Fotolia

Researchers from The University of Texas Health Science Center at San Antonio, the Texas Liver Institute and other institutions have identified a combination of pills that cures 9 of 10 hepatitis C patients.

National study conducted in the U.S.

The combination of the drugs sofosbuvir and simeprevir, with or without ribavirin, cured 93 percent of patients in 12 weeks, and was well tolerated by patients, according to the study published today in The Lancet.

Eric Lawitz, M.D., clinical professor in the School of Medicine at the UT Health Science Center and vice president of research and scientific development at the Texas Liver Institute, led the clinical trial conducted in the United States.

News of this study is important because encouraging people to take a simple blood test to diagnose hepatitis C could result in their being treated with an oral regimen that could prevent serious liver diseases such as cancer, cirrhosis or liver failure. Hepatitis C is the leading cause of liver transplants in the U.S. today.

Previous treatment hard to swallow

It is estimated that 3.2 million people in the U.S. have hepatitis C and most do not know they are infected. Historically, cure rates for hepatitis C patients with cirrhosis have been lower than 50 percent and the treatment has had numerous adverse effects. The previous standard of care with interferon involved a complicated regimen of shots and up to 18 tablets a day for up to 48 weeks, and subsequent six months of follow-up care to determine if the therapy was successful. There were also major side effects with the treatment, including rash, anemia and depression.

New era offers pills and higher cure rate

"We are now in the midst of a paradigm shift of moving away from complicated injection regimens that included interferon and often caused significant side effects with modest success rates," Dr. Lawitz said. "This trial provides a glimpse into the outcomes of sofosbuvir and simeprevir for treatment of hepatitis C. Both drugs are approved by the FDA but are not yet approved together for this treatment," he said.

All-oral regimens hold promise for a hepatitis C cure rate of more than 90 percent of patients, including those with liver cirrhosis (liver scarring). Participants in the study had the most common form of hepatitis C (genotype 1) and were difficult to treat due to either failing a previous course of interferon and ribavirin, or having cirrhosis.

More than 150 million people worldwide have chronic hepatitis C, a major cause of liver cirrhosis and liver cancer, with 350,000 to 500,000 deaths reported annually.

CDC urges Baby Boomers to get hepatitis C blood test

According to the U.S. Centers for Disease Control and Prevention, 75 percent of U.S. residents with chronic hepatitis C were born from 1945 through 1965. For this reason, the CDC recommends people born during these years have a one-time test for hepatitis C to prevent the risk of more serious health problems.

The study was funded by Janssen.


Story Source:

The above post is reprinted from materials provided by University of Texas Health Science Center at San Antonio. Note: Materials may be edited for content and length.


Journal Reference:

  1. Eric Lawitz, Mark S Sulkowski, Reem Ghalib, Maribel Rodriguez-Torres, Zobair M Younossi, Ana Corregidor, Edwin DeJesus, Brian Pearlman, Mordechai Rabinovitz, Norman Gitlin, Joseph K Lim, Paul J Pockros, John D Scott, Bart Fevery, Tom Lambrecht, Sivi Ouwerkerk-Mahadevan, Katleen Callewaert, William T Symonds, Gaston Picchio, Karen L Lindsay, Maria Beumont, Ira M Jacobson. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet, 2014; DOI: 10.1016/S0140-6736(14)61036-9

Cite This Page:

University of Texas Health Science Center at San Antonio. "New pill regimens cure hardest-to-treat hepatitis C patients." ScienceDaily. ScienceDaily, 28 July 2014. <www.sciencedaily.com/releases/2014/07/140728123856.htm>.
University of Texas Health Science Center at San Antonio. (2014, July 28). New pill regimens cure hardest-to-treat hepatitis C patients. ScienceDaily. Retrieved July 3, 2015 from www.sciencedaily.com/releases/2014/07/140728123856.htm
University of Texas Health Science Center at San Antonio. "New pill regimens cure hardest-to-treat hepatitis C patients." ScienceDaily. www.sciencedaily.com/releases/2014/07/140728123856.htm (accessed July 3, 2015).

Share This Page: